Michael Barbella, Managing Editor11.11.22
Sky Medical Technology Ltd. has appointed Fiona Young as director of its wound care therapy business. Young will spearhead and build-out Sky's geko device sales and marketing strategy in the wound care space.
"It is with great pleasure that we welcome Fiona Young to the Sky team. Fiona's impressive commercial track record in wound care makes her ideally suited to the development and delivery of our commercial strategy in wound care. Fiona's expertise will provide highly relevant and invaluable leadership in the engagement of wound care professionals willing to embrace innovation for better patient outcomes," Sky Medical Founder/CEO Bernard Ross said.
Young brings to Sky a proven track record in building international sales success in the wound care market. During her 20-year career, Young has worked in sales development roles at Crawford Healthcare and Lohmann & Rauscher, helping introduce and integrate new products into wound care pathways—and more recently as International Marketing & Direct to Consumer manager at Flen Health, a company that provides innovation in skin healing.
"I am excited to be joining Sky at this important time in the company's development. Sky has an exceptionally dynamic technology platform with multiple large market opportunities—wound care therapy being among the largest of these,' Young said. "I am delighted to be working with the Sky team and excited to lead a clinical partner advocacy programme that will help drive geko device adoption. The market is ripe for the introduction of the geko device, an innovation able to improve the lives of millions living with chronic wounds."
Worn at the knee, the geko is a neuromuscular electrostimulation device that gently stimulates the common peroneal nerve activating the calf and foot muscle pumps, resulting in increased venous, arterial and microcirculatory blood flow. The product transports oxygenated blood to the wound edge and bed to promote healing in patients with lower limb wounds.
The global wound care market is projected to reach $27.2 billion by 2027, driven by the growth of an aging population and the rising use of technological advancements in innovative wound care products.
Sky is a U.K.-based maker of wearable medical devices designed to heal chronic wounds. Through its mechanism of non-invasive neuromuscular electrostimulation, Sky has developed an NMES technology platform, OnPulse, embedded in the geko device. The company develops a range of products tailored to the needs of different medical application areas, selling both direct and through strategic partnerships or distributors in each major clinical area. Clinical areas of interest include chronic wound healing, the treatment and prevention of oedema (swelling) and venous thromboembolism prevention (VTE). The goal in each therapy is to partner with healthcare professionals to improve clinical outcomes and patient care while at the same time reducing cost for health systems.
"It is with great pleasure that we welcome Fiona Young to the Sky team. Fiona's impressive commercial track record in wound care makes her ideally suited to the development and delivery of our commercial strategy in wound care. Fiona's expertise will provide highly relevant and invaluable leadership in the engagement of wound care professionals willing to embrace innovation for better patient outcomes," Sky Medical Founder/CEO Bernard Ross said.
Young brings to Sky a proven track record in building international sales success in the wound care market. During her 20-year career, Young has worked in sales development roles at Crawford Healthcare and Lohmann & Rauscher, helping introduce and integrate new products into wound care pathways—and more recently as International Marketing & Direct to Consumer manager at Flen Health, a company that provides innovation in skin healing.
"I am excited to be joining Sky at this important time in the company's development. Sky has an exceptionally dynamic technology platform with multiple large market opportunities—wound care therapy being among the largest of these,' Young said. "I am delighted to be working with the Sky team and excited to lead a clinical partner advocacy programme that will help drive geko device adoption. The market is ripe for the introduction of the geko device, an innovation able to improve the lives of millions living with chronic wounds."
Worn at the knee, the geko is a neuromuscular electrostimulation device that gently stimulates the common peroneal nerve activating the calf and foot muscle pumps, resulting in increased venous, arterial and microcirculatory blood flow. The product transports oxygenated blood to the wound edge and bed to promote healing in patients with lower limb wounds.
The global wound care market is projected to reach $27.2 billion by 2027, driven by the growth of an aging population and the rising use of technological advancements in innovative wound care products.
Sky is a U.K.-based maker of wearable medical devices designed to heal chronic wounds. Through its mechanism of non-invasive neuromuscular electrostimulation, Sky has developed an NMES technology platform, OnPulse, embedded in the geko device. The company develops a range of products tailored to the needs of different medical application areas, selling both direct and through strategic partnerships or distributors in each major clinical area. Clinical areas of interest include chronic wound healing, the treatment and prevention of oedema (swelling) and venous thromboembolism prevention (VTE). The goal in each therapy is to partner with healthcare professionals to improve clinical outcomes and patient care while at the same time reducing cost for health systems.